Advances in epigenetic modulation-based therapies for lymphoma
10.3969/j.issn.1000-8179.2020.07.330
- VernacularTitle: 淋巴瘤表观遗传学靶向治疗的进展*
- Author:
Zhaoyi MIAO
1
Author Information
1. Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer
- Publication Type:Journal Article
- Keywords:
Epigenetics;
Lymphoma;
Targeted therapy
- From:
Chinese Journal of Clinical Oncology
2020;47(7):359-364
- CountryChina
- Language:Chinese
-
Abstract:
Lymphomas are a group of heterogeneous tumors originating from lymphocytes at various stages of differentiation . Epigenetics is an emerging discipline of science that studies heritable changes in the DNA sequences and gene expression patterns of organisms. Studies have shown that the development and progression of lymphomas are closely related to epigenetic abnormalities. Drugs targeting epigenetic abnormalities, including DNA methyltransferase inhibitors, histone deacetylase inhibitors, EZH2 inhibitors, PRMT inhibitors, and BET inhibitors, have been studied extensively and have shown many advantages in the treatment of lymphomas. This article reviews the recent advances in epigenetic drugs for treatment of lymphomas to provide new ideas for treatment strategies for lymphoma.
